Aurora Cannabis is focused on the medical cannabis market which has less competitors than the recreational market.
OWNERSHIP:
MedReleaf Australia – 100%
They provide patients in Australia with Aurora-branded products such as dried flower, oils and soft gels. Aurora also has a medical brand with MedReleaf called CraftPlant with products that are developed from Aurora’s Occo business and brings ultra-premium cultivars that are THC-dominant with a high percentage of terpenes to the Australian market. The products are produced under EU-GMP and are available in 10 gram containers.
Hempco Food and Fiber – 100%
Farmacias Magistrales – 100%
100% wholly-owned subsidiary Hempco Food and Fiber with a 56,000 sq ft state-of-the-art cultivation facility.
25% ownership in Alcanna.
9% ownership of CTT Pharmaceutical.
6.46% ownership in Micron Waste Technologies.
15.87% ownership in Radient Technologies.
51% ownership in Aurora Portugal which produces medical cannabis and derivative products in Portugal.
Aurora owns 50,1% of Bevo Farms which supplies vegetable growers and retailers of floral plants with wholesale and has been in business since 1986, operating 63 acres of greenhouses in British Columbia.
FACILITIES:
Aurora Coast’s primary focus is cannabis breeding which is done in Comox, Vancouver Island where the company’s facilities house a 21,000 sq ft greenhouse and a 10,000+ research building. It is home to one of the world’s largest genetic libraries for cannabis.
Aurora Leuna is a 107,500 sq ft German facility with 38,750 sq ft under production.
PARTNERSHIPS:
2017
The company signed a hardware supply agreement with Namaste Technologies involving Namaste distributing BC Northern Lights’ home cultivation systems and accessories through its online technology platform.
The company signed an exclusive hardware supply agreement with Namaste Technologies where Aurora offers a specially curated selection of industry-leading vaporizers from Namaste through its website and mobile app in the Canadian market with next day delivery except for in the Greater Tornoto area with same day delivery with Namaste being in charge of back-office support, including the handling of returns and warranty claims.
Acquired 33.6% of Hempco.
2018
The company acquired CanniMed.
The company acquired MedReleaf.
Increased ownership in Hempco to 52.7%.
The company entered into an exclusive licensing agreement with Alcanna for the rights to open retail cannabis stores under the Aurora brand name across Canada.
The company announced a private-label software agreement allowing Namaste to provide the company’s subsidiary CanvasRx with a customized version of Namaste’s patient acquisition tool, NamasteMD.com with a 2-year exclusivity period, as well as desktop and mobile applications for Google Android and Apple iOS platforms.
The company signed a supply agreement with BZAM Cannabis allowing for Aurora to purchase up to 20% of BZAM’s annual production of organic cannabis.
The company signed an exclusive licensing deal with CTT Pharmaceutical for their sub-lingual wafer technology to their company called CanniMed with joint exclusivity of the distribution in Canada of CTT’s patented drug delivery technologies.
The company started an international research project with McGill University examining the therapeutic impact and human health outcomes of CBD oil as a therapy for chronic pain and related anxiety and depression.
The company reached an agreement with Shopify selling medical and recreational cannabis globally through their global e-commerce platform.
The company started a strategic partnership with Evio Beauty Group to collaborate and develop a line of co-branded hemp seed oil cosmetic products and a collection of CBD-infused cosmetic products.
The company started a collaboration agreement with Micron Waste Technologies involving the optimization of Micron’s technology for the treatment of organic waste generated in the cultivation and production of cannabis products. Micron installed a digester unit at one of Aurora’s facilities for the joint process of optimizing the digestor for the cannabis industry. Once successfull, the company plans to acquire several units for its facilities. Under the terms of the agreement, Micron retains the IP related to the digestor and will pay Aurora a 4% royalty for every unit sold to other licensed producers globally.
The company bought Wagner Dimas’s technology for pre-rolls from CannaRoyalty.
The company entered the global softgel category through a strategic investment in Capcium Inc securing a 19.9% ownership as well as an agreement to produce high quality cannabis-based softgels for patients. Through the deal, Capcium will be the exclusive manufacturer of Aurora’s North American cannabis softgel products.
The company signed a supply agreement with Ascent Industries for flower and trim up to 20,000 KG of dried cannabis flower and up to 6,000 KG of cannabis trim per year from its Canadian operations. The agreement was valid for 5 years with a minimum supply of 12,000 KG per year.
The company has launched a cannabis brand in Germany called Cannabis Klenk through a collaboration agreement with Heinrich Klenk & Co. KG which is sold to German pharmacies through Klenk’s pharmaceutical wholesale distribution network.
The company started a 51%-ownership JV with Alfred Pedersen & Søn in Denmark by the name of Aurora Nordic Cannabis A/S. The JV will focus on the cultivation and sales of cannabis in Denmark, Sweden, Norway, Finland and Iceland.
The company sold medical cannabis to Czech Medical Herbs that will in turn supply pharmacies in the Czech Republic.
The company was selected for the supply of medical cannabis by the Luxembourg Health Ministry with an initial purchase order for approximately 20 KG. The next year, the company was again selected, this time as an exclusive supplier from a public bid for a smaller quantity of product.
The company was the only company to win the public tender with the Italian government through the Ministry of Defense for medical cannabis.
Shortly after announcing an exclusive deal with Farmacias Magistrales, the company decided to acquire the company the week after. Farmacias has a a license to import medical marijuana into Mexico and has licenses for the storage of raw CBD and THC materials, as well as to manufacture and distribute CBD and THC products. The company has distribution towards 80,000 retail points for CBD products and 500 pharmacies and hospitals for THC products as well as a 12,000 sq ft facility for the production of pharmaceuticals.
2019
The company acquired full ownership of Hempco Food and Fiber.
The company was awarded the maximum number of 5 of the 13 lots in a tender over a period of 4 years with a minimum supply of 4000kg by the German Bundesinstitut für Arzneimittel und Medizinprodukte BfArM as one of three winners in the public tender to cultivate and distribute medical cannabis in Germany.
The company got first approval for its oil as a medicinal cannabis product in Ireland and is the second product to gain the authorization under the MCAP in the Irish market. The MCAP was scheduled to run for 5 years at the time.
The company and CanniMed Therapeutics introduced PINs, product identification numbers for 78 medical cannabis products to better facilitate and track insurance coverage for their Canadian patients.
The company opened its flagship retail store in the West Edmonton Mall, the biggest in North America. The store is 11,000 sq ft and is not just a retail store but also an immersive experiential space.
The company was selected as the only winner out of 5 of the Italian cannabis tender which secured a 2-year contract to continue supply Italy with a minimum of 400 KG medical cannabis.
The company entered global licensing arrangements with EnWave Corporation involving a royalty-bearing commercial license agreement providing Aurora with the exclusive rights to EnWave’s patented Radiant Energy Vacuum drying technology for the production of cannabis materials in the European Union, excluding Portugal. The company secured exclusive license options for both Australia and South America, excluding Peru, exercisable pursuant to minimum REV-machine purchase order requirements. The company also signed a non-exclusive sub-license to use REV technology in Canada.
The company started an exclusive multi-year global partnership with UFC aiming to advance research surrounding hemp-derived CBD products as well as athlete wellness and recovery, education and product development. The research will be conducted at the UFC’s Performance Institute in Las Vegas, Nevada, in collaboration with UFC’s sports performance team, as well as with athletes who choose to participate in the studies. Clinical studies will focus on pain management, inflammation, injury/exercise recovery, and mental well-being.
The company entered into a strategic relationship with Grow Group for the UK market.
The company received an order to Luxembourg for 20 KG of cannabis for 50,000 EUR.
The company won the trust of the Italian medical cannabis market as they were the sole winner to supply medical cannabis in 2019, however the price at which the government buys the cannabis is rather low, coming in at 1.73 EUR per gram. This has extended their time in the Italian market, as in 2018, Aurora was the sole winner of applicants to process 100 kilograms.
Germany: Aurora Cannabis was awarded the maximum number of 5 out of 13 lots in 2019 over a period of four years with a minimum supply of 4,000 kg in the cannabis production tender to cultivate and distribute medical cannabis in Germany. Aurora’s bid received the highest ranking out of all concepts submitted with the criterium: facility design, quality, security and logistics. Their German manufacturing site has EU-GMP certification.
2020
The company entered a strategic medical supply agreement with Cantek in Israel involving supplying the company with 4,000 KG bulk dried flower annually over a 2-year period.
Aurora in combination with Etypharm Group was selected as the primary supplier for the three dried flower lots they applied (high-THC, CBD-balanced and high-CBD) for in the French medical cannabis pilot program.
2021
The company renewed its deal with Grow Group for another 2 years, now with a market access services agreement for the market in the UK.
The company started selling CBD oil in 3% and 10% concentrations from its own GMP-certified cannabis processing facilities in the country.
The Company has a strategic supply agreement with Cantek Global and intends to supply a minimum of 4,000 KG bulk-dried flower annually to Israel.
The company started a strategic agreement with MedReleaf Australia for a 5 year supply agreement where MedReleaf will be the exclusive supplier in Australia of Aurora’s MedReleaf, CanniMed and Aurora brands. Products covered by the agreement will be EU-GMP certified and include dried flower, oils, and soft gels, as well as future products employing new delivery mechanisms.
The company announced a deal with Great North Distributors naming them the exclusive representative for Aurora’s portfolio of brands across Canada’s retail environment.
The company announced a manufacturing agreement with the Valens Company to manufacture a new seasonal offering in the mint category under the brand Drift Turbo using SōRSE by Valens emulsion technology.
The company, together with 22nd Century Group, announced a three-way non-exclusive agreement for the licensing of biosynthesis intellectual property to Cronos Group which intends to assist in the advancement of research and development on the biosynthesis of cannabinoids.
2023
The company launched a tracking program in partnership with Strainprint, designed to support and empower cannabis patients to find the right medicine.
The company started a partnership with Herbarium for the launch of the company’s full-spectrum, single-source 3% CBD oil under the Herbarium brand in Brazil.
The company launched Aurora Lab which is a research and education program designed to strengthen two-way conversations with patients, retailers, budtenders and consumers.
The company and Etypharm were continually selected by the French General Directorate of Health as the exclusive suppliers of dried medical cannabis flower until the end of the French trial period which was extended to March 2024.
As France integrates medicinal cannabis into its healthcare system, the company and 2 others were given the exclusive right to supply patients with medicinal cannabis.
2024
The company received Australia’s TGA GMP-certification for its River and Ridge facilities in Canada.
The company partnered with Script Assist for its products to be available on its platform in the UK.
The company was granted 2 licenses by the Federal Institute for Drugs and Medical Devices in Germany. 1 of the licenses grants it continued domestic cultivation, which has been underway for 2 years. The new license allows the compant to cultivate an additionally approved product.
The company partnered with Cogent International Manufacturing, a subsidiary of wellness innovator Vectura Fertin Pharma for 2 years where Cogent will launch its newly developed Luo CBD lozengeon Aurora’s Canadian medical marijuana patient platform, providing access to patient feedback that will be used to validate the product proposition and patient responses while building real-world patient data for future analysis. After the launch of the CBD lozenge, the companies intend to pursue opportunities for the potential commercialization of other Vectura Fertin Pharma medical marijuana products in Canada. The products will be manufactured, packaged and labeled by Cogent for sale and distribution by Aurora through its leading direct-to-patient e-commerce sales channel.
The company was granted 2 licenses by the Federal Institute for Drugs and Medical Devices under Germany’s new Medical Cannabis Act allowing for continued domestic cultivation. Under the new license, the company can also cultivate an approved additional product and the company said it will also receive a dedicated R&D license, allowing for the trial of up to 7 additional novel cultivars at the company’s local EU GMP facility in Leuna, Germany.
The company is innovating its operations via research in auto-flowering technology which doesn’t have to rely on changes in light cycles and has thus far resulted in improved potency and yield. The work provides foundational insight into the flowering mechanism in cannabis which will support future breeding strategies and can be leveraged to revolutionize outdoor cannabis cultivation in high-latitude regions, such as Canada.
The company received US Patent 12,002,546: “Methods of Determining Sensitivity to Photoperiod in Cannabis” allowing for its breeding program to identify and select for the auto-flowering trait.
The company closed its operations in Uruguay.
The company announced a collaboration project by the name of Genomics-Enabled Aroma Breeding in Cannabis which was made possible through a research grant provided to the University of British Columbia by Genome British Columbia. The project focuses on validating genetic and chemical markers for fruity aroma in cannabis.
The company launched a range of premium medical cannabis oils with a variety of cannabinoid ratios to suit diverse patient needs, available for physicians to prescribe in Australia. The new products also allow doctors to tailor treatments more precisely.
The company acquired the remaining 90% of MedReleaf Australia for 50 million AUD.
The company launched Vectura Fertin Pharma’s Luo CBD lozenges in Canada with distribution provided by Aurora through its direct-to-patient platform which provides access to patient feedback on the product, used for validation of the product proposition and real-world patient data for future products. The companies will look into the potential commercialization of other of VFP’s medical cannabis products for the Canadian market.
The company launched cannabis oil products through MedReleaf Australia for the Australian market with strains that are designed for targeted and effective relief containing a variety of THC and CBD ratios.
The company sold its interest in Aurora Netherland BV which owned a research and development facility and related assets of Dutch cannabis producer Growery.
2025
The company launched IndiMed offering high quality cannabis and their first domestically grown cannabis products into the German medical market from its facilities in Leuna.
The company entered into a 3-year agreement estimatedly worth 27 million CAD with an option to extend with SNDL for the supply of premium cannabis flower to Aurora.
The company discovered a source of genetic resistance against powdery mildew in the plant.
The company expanded its offerings of pastilles in Australia.
The company expanded the eligibility of its patients for their medical compassionate pricing program in Canada from $40,000 CAD to $60,000 CAD.
The company introduced its first inhalable resin cartridges for patients in the UK.
The company’s facility in Brampton, Ontario was awarded with a European Union Good Manufacturing Practice certification.
The company inked a deal with local pharmacy wholesaler Leafio in Australia involving MedReleaf Australia that will provide product from Aurora’s portfolio of brands to 4,000+ pharmacies serviced by Leafio in the country.
The company expanded its IndiMed brand to Australia.
The company launched an affordable medical cannabis brand in Germany called Daily Special.
The company reported significant progress in its powdery mildew resistance program, transferring its novel PM2 genetic resistance into elite cannabis lines and moving into production trials.
2026
The company was granted community plant variety rights by the EU’s Community Plant Variety Office for 2 of its proprietary cannabis varieties; Sourdough and Farm Gas.
The company acquired Safari Flower Company and its 59,000 sq ft indoor cultivation and manufacturing facility in Ontario, Canada.
The company was granted Canadian Plant Breeders’ Rights for 2 proprietary cultivars: Farm Gas and Driftwood Diesel. This gives Aurora exclusive rights to grow, propagate, and sell products from these genetics.
BRANDS:
Drift Turbo offers a hard peppermint candy with THC as well as flower, gummies and a form of high-potency gummies called glitches.
San Rafael ’71 is a premium brand with house-bred strains bringing innovative products in the form of flower, pre-rolls, infused pre-rolls, concentrates, vapes and edibles. Sourdough Shortcuts are infused with pure live resin THCA diamonds offering joints with 50-56% THC.
MedReleaf – 5 percent of net profits from Strain for Heroes products will support veteran organizations in Canada.
The company has introduced Honour, a premium indica cannabis strain created with input from Canadian veterans. Valour is a cannabis cultivar designed for veterans, by veterans.
CraftPlant is an EU-GMP-certified medical cannabis brand in the Australian market.
KG7 is a CBD brand developed for adult consumers with an active lifestyle and can be bought on Reliva’s website pectin-based gummies made with natural flavors and colors, topical creams formulated with ingredients such as arnica and shea butter, gluten-free CBD oil and drink mixes made with 100% hemp-derived CBD isolate and zero THC.
Tasty’s offers vapes and infused pre-rolls with 50% THC at good prices.
IndiMed is its first German-cultivated medical cannabis brand.
Daily Special offers dried flower and is positioned as a qualitative, reliable and affordable brand.